Acorda announces availability of MS treatment

HAWTHORNE, N.Y. A new drug by Acorda Therapeutics for treating multiple sclerosis has become available, Acorda announced.

The drug maker announced Monday the availability of Ampyra (dalfampridine) extended-release tablets in the 10-mg strength. The drug received approval from the Food and Drug Administration on Jan. 22.

“The majority of people with MS experience a decline in their walking as their disease progresses,” Acorda president and CEO Ron Cohen. “The availability of Ampyra therefore gives people with MS and their physicians an important new therapeutic option.”

The company is offering a patient-assistance program for the drug, managed by an unspecified third-party organization, and people who meet certain income requirements may receive the drug for free, while those with Medicare Part D coverage may be eligible for financial assistance. In addition, Acorda has created a co-payment program whereby many eligible patients with private insurance pay $40 for a one-month prescription.